Buy TB-500 in Australia
TB-500, a seven-amino-acid chain copied from thymosin beta-4 that binds free actin, is supplied in Australia by Australian Research Peptides in a tamper-sealed 10 mg vial, its contents dried to a solid. Binding actin is how a cell rebuilds its internal framework and pulls itself towards a wound, and the same chain sets new blood vessels sprouting, which is why it speeds skin repair and leaves a mended tendon taking more force before it fails. Vials are posted domestically to every state and territory once a batch lands. In vitro research purposes only, never for people or animals.
Tissue Repair Research · Lyophilised Powder · Batch-tested · SKU ARP-TB500-10
$119.99
2+ vials: 5% off — applied automatically in the cart
Presentation
10 mg per vial
Grade
High-Purity Research Grade
Form
Lyophilised Powder
Category
Tissue Repair Research
Currently out of stock — stocked lines dispatch same business day before 12pm AEST, Mon–Fri
Tracked shipping Australia-wide ·typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. Any amounts shown are reported from published studies, with the species or trial population named. ARP gives no dosing, medical or therapeutic guidance of its own.
TB-500 · 10 mg
$119.99
Frequently Bought Together
About TB-500
Published work on TB-500 sits in animal and cell-culture models. A 2003 paper in Wound Repair and Regeneration reported that the seven-amino-acid peptide promoted dermal wound repair in 26-month-old mice. A second 2003 paper, in the FASEB Journal, found the same motif was the part of thymosin beta-4 needed for angiogenic activity, using endothelial cell migration assays and vessel sprouting from the chick aortic arch.
TB-500 is a heptapeptide, which means a chain of seven amino acids. The sequence is Leu-Lys-Lys-Thr-Glu-Thr-Gln, written LKKTETQ, with an acetyl cap on the N-terminal end. Those seven match positions 17 to 23 of thymosin beta-4. That distinction matters, because the two names get swapped in print and a study on the 43-amino-acid protein is not a study on this fragment.
Australian Research Peptides supplies TB-500 in one strength, as a freeze-dried powder sealed inside a tamper-evident glass vial. PubChem records the free acid form as C38H68N10O14, around 889 g/mol, under CAS 885340-08-9. Those values are not printed on this listing as a specification, because the salt and terminal form of the supplied material is not confirmed and both figures move with it. The certificate of analysis describes the batch in hand.
Content reviewed
Further reading: BPC-157 vs TB-500: What Is the Difference?
TB-500 specifications, storage and shipping
- Compound: TB-500
- Also known as: TB-500 (N-terminally acetylated thymosin beta-4 fragment 17-23)
- Class: Synthetic acetylated heptapeptide; actin-binding fragment of thymosin beta-4
- Appearance: White to off-white lyophilised powder
- Sizes & SKUs: 10 mg (ARP-TB500-10)
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: High-purity research grade
- Purity verification: HPLC-assayed on every batch to a minimum of 99% purity — the measured result for your batch is stated on its Certificate of Analysis
- Identity confirmation: Mass spectrometry
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
Every batch undergoes HPLC purity analysis and mass-spectrometry identity confirmation. No laboratory report is published for this line yet. The COA library lists every product and strength, and says which reports are available.
This line is currently out of stock. Stocked lines ordered before 12pm AEST on a business day are dispatched the same day with tracked, discreet shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about TB-500
This question guide from Australian Research Peptides covers TB-500 in Australia: what the listing contains, live buying and delivery questions, research context, handling, testing and comparisons. Start with the quick answers, then open the topic group that matches your search.
Buying, price and availability
Australian Research Peptides is where TB-500 — also searched as TB500, TB4 or thymosin beta — can be bought in Australia, listed under stock code TB500 as a 10 mg lyophilised vial for in vitro research. Each batch is HPLC-tested before release, and the CoA library lists every certificate ARP has published, per product and strength. TB-500 has nothing to send today, and the same weekday cut-off applies once a batch lands by Express or tracked standard post, covering every state and territory — all posted domestically, so customs never sees it.
Australian Research Peptides runs a restock alert for TB-500: leave an email address against the line and one message is sent when stock lands. It is a single notification rather than a subscription — no newsletter, no follow-up mail, and the address is used for that one purpose. Nothing is charged and nothing is reserved by registering.
Australian Research Peptides is the supplier of TB-500 in Australia, listing the single 10mg vial as stock code TB500 within its Tissue Repair Research range. Searches for tb500, thymosin beta or tb4 resolve to the same ARP record. Goods post from inside the country, so no customs step applies. HPLC testing backs each batch, and the CoA library shows which products and strengths currently have a published certificate. Express Post and tracked standard post cover every state and territory, and the weekday 12pm AEST cut-off will govern dispatch again once a batch lands.
TB-500 sells at one price per 10 mg vial, since Australian Research Peptides lists it in a single size with no ladder of strengths inside the line. That figure is held in the live stock record rather than fixed into prose. Comparing it with the two blends that also contain TB-500 is not like for like, because their price buys several peptides at once. Each line earns the multi-vial discount on its own.
TB-500 is sold direct by Australian Research Peptides, which supplies from within Australia and posts nationally rather than drop-shipping from overseas. Two payment routes exist: PayID, or a direct bank transfer — cards, wallets and crypto are not accepted.
TB-500 is supplied by Australian Research Peptides and sold by no Australian pharmacy, Chemist Warehouse included. Thymosin beta-4 fragments hold no registration in this country, so there is no dispensable product for a pharmacist to supply and no route to order one in. ARP lists TB-500 as a 10 mg research vial for laboratory use.
Identity, names and exact format
TB-500 is also written TB500 or TB 500, and formally as N-terminally acetylated thymosin beta-4 fragment 17-23. Searchers type tb4 or beta thymosin too, and databases index it under CAS 885340-08-9 and PubChem CID 62707662. Thymosin beta-4 alone names the 43-residue parent protein, not this seven-amino-acid chain. All those names point at one vial, posted by Australian Research Peptides from inside Australia, so no customs desk is involved.
TB-500 is a synthetic peptide of seven amino acids corresponding to the actin-binding region of thymosin beta-4, a protein that occurs naturally in most mammalian cells. It is a fragment rather than the whole protein, which is the distinction the two names conceal and the reason the two are not interchangeable in a study.
A TB-500 vial holds one freeze-dried compound, the acetylated heptapeptide Ac-LKKTETQ, under a tamper-evident seal. The acetyl cap belongs to the molecule itself rather than being something added to it, which is why Ac- sits inside the name. Nothing else shares the glass. Both blends that mention TB-500 spread their stated milligrams over more than one peptide.
TB-500 contains seven amino acids: Leu-Lys-Lys-Thr-Glu-Thr-Gln, written LKKTETQ. Those residues come from positions 17 to 23 of thymosin beta-4, which has 43 amino acids in all. The acetyl group on the front end is a chemical cap rather than an eighth amino acid, so it changes the measured mass without changing the count. Seven residues make TB-500 a heptapeptide.
Research context and evidence
TB-500 is the actin-binding stretch of thymosin beta-4, lifted out and made on its own. Actin is the protein cells build their internal scaffolding from, and UniProt annotates the parent as binding free actin units and stopping them assembling. In the FASEB Journal work, that same seven-amino-acid motif was the part needed for angiogenic activity in cell assays, and peptides missing any of it were inactive. That is a mechanism measured in the lab.
Published TB-500 research is preclinical work in animals and cell culture. The seven-amino-acid fragment appears in dermal wound models and in angiogenesis assays measuring endothelial-cell migration and vessel sprouting. Nothing equivalent has been run in people and published. This evidence context does not establish what happens in people or animals outside those studies.
Two 2003 papers carry most of the published work on this seven-amino-acid peptide. In Wound Repair and Regeneration it promoted dermal repair in aged mice, 26 months old. In the FASEB Journal it matched full-length thymosin beta-4 in endothelial migration and chick aortic arch sprouting, both near-identical at about 50 nM. Nothing comparable has been published in people.
TB-500 has been given to rats at 60 micrograms per kilogram a day. That figure comes from Biçer's 2026 study of Achilles tendon repair, where the peptide went into the abdominal cavity for four weeks. Eight male Sprague-Dawley rats made up each of the four groups. No human dose for the fragment has ever been published, so there is no human figure to report alongside it.
No half-life for TB-500 itself has ever been published. What exists is a 2024 study by Rahaman and colleagues in the Journal of Chromatography B, which tracked breakdown products in rat urine instead: Ac-LK was most abundant across the first six hours, while Ac-LKK stayed detectable out to 72. Those authors went further, proposing that wound-repair activity reported in earlier literature may belong to the metabolite Ac-LKKTE rather than the parent chain.
TB-500's parent protein, thymosin beta-4, has a substantial animal literature and reached clinical trials in wound and eye conditions; the seven-residue fragment sold as TB-500 has far less behind it. No controlled human trial of the fragment itself has been published. So the honest position is that the evidence people cite for TB-500 is mostly evidence about something larger.
The animal studies behind TB-500 typically ran daily administration across one to several weeks before measuring repair outcomes, so weeks is the timescale in the published record. Nothing has measured a human timeline at all, which means any specific figure in weeks quoted for people is extrapolation rather than data.
There is no published record of what follows ceasing TB-500. Its evidence base is preclinical — dermal wound repair and severed-tendon models in rodents — and those designs measure a treatment window rather than any recovery period beyond it. Nothing describes dependence, tapering or rebound, and nothing excludes them either, because the observation was simply never made. That gap is a genuine limitation.
No controlled human trial of TB-500 has been published, so any side-effect profile quoted for it was never measured — including a favourable one. Animal studies reported tolerance at the doses and durations tested, typically weeks. Absence of reported harm in a short rodent study is not the same as evidence of safety in a person.
TB-500 is studied in injury models, not used to treat injuries in people. Biçer's 2026 rat experiment severed the Achilles tendon, repaired it, then tested the join four weeks later. Tendons from the TB-500 animals took more force before failing, and their tissue scored better under the microscope. Philp's 2003 paper in Wound Repair and Regeneration reported faster skin repair in mice aged 26 months.
Handling, storage and measurements
Expect very little to see: TB-500 is an acetylated seven-amino-acid fragment, among the shortest chains stocked anywhere, and ten milligrams of it dries to a wisp on the floor of the glass — sometimes no more than a dull patch where the surface stops being perfectly transparent. Sublimation leaves solid exactly where frozen liquid sat, so a cake broken up in transit can look like nothing whatsoever.
TB-500 carries two lysines and a glutamate in its seven-amino-acid chain. GenScript names exactly those amino acids as the ones to keep in a desiccator inside a tightly capped vial. TB-500 has no cysteine, methionine or tryptophan, so oxidation is not the main worry for TB-500. Keep the sealed dry vial in a freezer, out of bright light. Bachem says a desiccator should bring the glass back to ambient before anyone breaks the seal, because absorbed moisture lowers peptide content.
TB-500 dissolves readily in water, because six of its seven amino acids are polar or charged. Warm the sealed vial, run the liquid down the glass, then swirl instead of shaking. The volume you choose sets the strength. Add 1 mL to a 10 mg vial for 10 mg/mL, 2 mL for 5 mg/mL, or 5 mL for 2 mg/mL. Australian Research Peptides' reconstitution calculator guide does the sum for any volume.
TB-500 ends in glutamine, one of the residues Bachem and the NIBSC both flag as shortening a dissolved peptide's life. Once mixed, hold it between 2 and 8 °C and use it inside eight to twelve weeks, the window Australian Research Peptides publishes for every HPLC Verified line. Keep it dark. Freeze single-use aliquots below -15 °C if you need longer.
TB-500 is supplied as a single 10 mg vial, so the volume of diluent added is what sets the concentration and it changes nothing about the quantity. Two millilitres produces 5 mg per mL, one millilitre produces 10 mg per mL, and five millilitres produces 2 mg per mL. Any other figure is milligrams divided by millilitres. More water does not weaken the peptide, only the solution — the vial holds the same 10 mg either way.
TB-500 is a short, readily soluble fragment that normally clears without difficulty, so a milky look immediately after water goes in is usually foam rather than the peptide. Give it several undisturbed minutes. Anything staying opaque, or fine strands drifting through the liquid, means something besides air is present — that is aggregation, and further swirling will not reverse it.
Yes, TB-500 ships as a dry powder, and bacteriostatic water is what laboratories normally use to dissolve it. The sealed glass holds nothing but the acetylated seven-amino-acid peptide, so only the diluent is added. Australian Research Peptides carries bacteriostatic water on its own catalogue line, sold by volume where TB-500 is sold by mass. Diluent is what that liquid is called once it has a job to do.
TB-500 is typically used at larger amounts per draw than the repair peptides it sits beside, so a 10 mg vial yields fewer draws than the same weight of BPC-157 — five at 2 mg, ten at 1 mg, twenty at 500 mcg. Milligram for milligram it goes just as far; draw for draw it does not.
Testing and batch documents
Australian Research Peptides tests every TB-500 batch before supply. TB-500 carries the HPLC Verified grade. Identity work has to account for the acetyl cap because that group adds weight and an uncapped seven-amino-acid chain lands lower on the scale. Any exact-strength batch document describes the material tested rather than a catalogue specification. No matching certificate is currently published for this product and strength.
Testing settles the confusion that follows TB-500 around. Mass spectrometry weighs what is in the vial, and seven amino acids weigh nowhere near a 43-amino-acid protein, so the scale tells them apart. Chromatography sorts the sample by how fast its parts travel through a column, then reports the share sitting under a single peak. Neither result speaks to microbial or endotoxin status.
Ordering, payment and Australian delivery
You will know a TB-500 payment has been matched because a confirmation email follows it; until that arrives, the order is placed but not paid. Payment is by PayID or bank transfer only. If the confirmation has not come through well after your bank shows the money gone, that is the point to contact support with the reference.
Free Standard tracked post needs two TB-500 vials; one falls short. A third takes the order past the separate Express Post waiver, which sits higher again. TB-500 is frequently ordered beside BPC-157, and that pairing reaches the standard threshold without a second TB-500 vial at all. Australian Research Peptides sets both waivers as order totals rather than per-product rules, so everything in the same order counts toward them.
Expect TB-500 in 2–5 business days on standard tracked post, and in 1–2 on Express Post to most of the country. If nobody is home when the parcel arrives, the carrier's usual action is a card and a nearby collection point rather than a return to sender, though signature on delivery — opt-in, never pre-ticked — changes what happens at the door.
Syringes are the consumable to think about with TB-500, because it is used at larger amounts per draw than most research peptides — fewer draws from a vial, so a smaller pack goes further than it would with BPC-157. Bacteriostatic water is still required, and a 3 mL vial suits a single 10 mg TB-500 vial.
Access, approval and sport questions
TB-500 is a Schedule 4 substance in Australia and also sits at Appendix D clause 5 of the federal Poisons Standard. Schedule 4 means prescription only. Appendix D goes further and reaches possession — nobody may hold a listed poison without authority. Both TB-500 and thymosin beta 4 are named. Australian Research Peptides sells this vial for in vitro laboratory research, and never for administration to a person or an animal.
TB-500 has never been approved as a medicine, by American regulators or by any other. No controlled human trial of the fragment has been published either, which sits a long way short of a licence. Human trials of full-length thymosin beta-4 are a separate programme on a larger molecule, and their standing does not transfer across.
TB-500 and thymosin beta-4 appear under growth factors on the World Anti-Doping Agency's prohibited list. Athletes should also know that the presence of a substance is what triggers a finding, not the intent behind it, and that a supplier describing something as a research chemical has no bearing on an anti-doping rule.
TB-500 is prescription-only under Schedule 4, and its Appendix D clause 5 entry goes further still, reaching possession rather than supply alone. Australian Research Peptides asks for no prescription and could not act on one, because the vial is laboratory research material and not a dispensable medicine. Anyone whose purpose falls outside bench research should take advice from the TGA or a lawyer.
TB-500 is not an approved medicine anywhere in the world, so no overseas licensed product exists to bring in, and personal importation of unapproved goods is governed by the TGA with Border Force enforcing at the frontier. It is separately prohibited in sport at all times. Australian Research Peptides supplies TB-500 from Sydney, so an order placed here is never presented at customs.